Iqvia Hldgs Inc - IQV STOCK NEWS

IQVIA (NYSE:IQV) recently won a significant legal battle against Veeva Systems (NYSE:VEEV) in the U.S. District Court of New Jersey. The court sanctioned Veeva multiple times for engaging in the destruction of evidence and covering up its wrongdoings, including the misappropriation of IQVIA's intellectual property. The ruling includes limitations on the use of evidence at trial and an award for legal fees. IQVIA expressed satisfaction with the decision, highlighting Veeva's deceitful practices and reinforcing the need for intellectual property protection.

IQVIA announced a collaboration with Corium, Inc. to support the launch of AZSTARYS™, a new treatment for ADHD approved by the FDA on March 2, 2021. This collaboration aims to enhance market engagement and streamline commercialization efforts. IQVIA will utilize its technology, analytics, and field services to connect healthcare professionals with Corium’s ADHD expertise. The partnership promises efficient engagement, leveraging IQVIA's Orchestrated Customer Engagement platform to maximize outreach. This initiative marks a significant step in providing effective treatment options for patients aged six and older.

IQVIA announced its innovative approach, Connected Intelligence, aimed at enhancing insights and decision-making in the life sciences sector. This strategy integrates IQVIA’s extensive healthcare data, advanced analytics, and technologies to facilitate faster drug development. Key initiatives include:

• Accelerating over 350 clinical research studies for COVID-19.
• Supporting 60 decentralized clinical trials in 40 countries.
• Linking real-world data for disease understanding and drug discovery.

IQVIA aims to improve societal health outcomes through innovation and significant investments in the healthcare ecosystem.

IQVIA Holdings Inc. reported a strong first quarter of 2021 with revenues of $3,409 million, marking a 23.8% increase year-over-year. Technology & Analytics Solutions revenue grew by 20.7%, while Research & Development Solutions surged by 29.6%. The company's backlog reached $23.2 billion, with expectations to convert approximately $6.5 billion to revenue in the next year. Adjusted EBITDA rose to $744 million, up 32.4%. As a result, IQVIA raised its full-year guidance for revenue and earnings per share, projecting significant growth driven by continued demand in life sciences.

IQVIA Holdings Inc. (NYSE:IQV) will release its first-quarter 2021 financial results on April 22, 2021, before the market opens. A conference call and webcast led by the management team will take place at 9:00 a.m. ET on the same day. Investors can access the earnings release on the IQVIA Investor Relations website. IQVIA is a global leader in analytics and technology solutions for the life sciences industry, employing approximately 70,000 individuals across 100 countries.

Moleculin Biotech, Inc. (Nasdaq: MBRX) has partnered with IQVIA Biotech to initiate clinical trials for WP1122, a drug aimed at treating COVID-19. The decision stems from delays in obtaining FDA approval due to the unavailability of validated COVID-19 animal models in the U.S. However, the company believes it has completed necessary preclinical testing to qualify for foreign IND submission. WP1122 is designed to enhance the drug-like properties of 2-deoxy-D-glucose (2-DG), which has shown efficacy against SARS-CoV-2.

Quest Diagnostics (NYSE: DGX) has announced the sale of its minority share in Q² Solutions to IQVIA (NYSE: IQV) for $760 million in cash. This divestiture aligns with Quest's strategy to focus on diagnostic information services. Since 2015, Q² Solutions operated as a joint venture, with IQVIA owning 60% and Quest 40%. Despite the sale, Quest will remain the preferred laboratory provider for Q² Solutions under a multi-year agreement, allowing them to continue offering complementary lab testing services.

IQVIA Holdings Inc. (NYSE:IQV) has completed the acquisition of Quest Diagnostics' 40% minority share in Q² Solutions for $760 million. This acquisition provides IQVIA full ownership, enhancing its capabilities in clinical laboratory services. The transaction is cash-funded, maintaining IQVIA's target net leverage ratio. The acquisition is expected to be accretive to IQVIA's Adjusted Diluted EPS, with revised guidance for 2021 set between $7.89 and $8.20. This move strengthens IQVIA's market position and service offerings while ensuring Quest remains a key laboratory partner.